主要研究方向：

    围绕心血管疾病的基础与临床转化研究，重点开展射血分数保留型心力衰竭（HFpEF）及心肌纤维化、心脏重塑的发病机制研究，聚焦心外膜脂肪、脂质代谢异常、炎症免疫及能量代谢相关信号通路在心血管疾病中的作用；同时开展心血管罕见病及遗传性脂质代谢疾病的精准诊断与临床队列研究，并结合多组学手段与前瞻性临床研究，推动新型治疗靶点和干预策略的转化应用。

2014.09-2015.10  美国波士顿大学，博士后

2007.03-2010.06  瑞典卡罗林斯卡医学院, 分子医学，博士

2006.09-2007.02  瑞典卡罗林斯卡医学院, 瑞典国Si奖学金访问学者

2001.09-2004.07  重庆医科大学, 内科学，硕士

1998.07-2001.08  重庆医科大学附属第一医院, 住院医师规范化培训

1993.09-1998.06  重庆医科大学, 临床医学，学士

2025.09-至今     重庆大学附属中心医院，心内科主任，主任医师，博士研究生导师

2024.09-至今     重庆大学附属中心医院，心内科主任，主任医师

2023.09-2024.08  重庆医科大学附属第一医院，教授

2017.09-2024.08  重庆医科大学附属第一医院，主任医师

2012.06-2017.08  重庆医科大学附属第一医院，副主任医师，副教授，硕士导师

2004.06-2012.05  重庆医科大学附属第一医院, 总住院医师(1年), 主治医师

2001.09-2004.06  重庆医科大学附属第一医院, 住院医师规范化培训

1998.07-2001.08  重庆医科大学附属第一医院，住院医师

国家心血管病专家委员会第一届心血管代谢医学专业委员会委员2025-2028

中国医师协会心血管病分会心脏罕见病学组副组长2025-2028

中国卒中学会心血管病分会第二届委员会委员2025-2028

牵头成立重庆市卒中学会高血压分会，担任分会主任委员，举办第一届活动和成立大会。任职时间2025-2028

1. Jian Liu, Lei Gao, Junlong Chen, Zhenghao Li, Wenhang Zhao, Shiwei Qin, Xuesong Wen, Dongying Zhang. Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States. American Journal of Preventive Cardiology, 2025, 23:101049. IF=5.9.

2. Junlong Chen, Ruo'nan Xiao, Lei Gao, Yujiao Zhou, Shiwei Qin, Yichen Wang, Panpan Feng, Jun Gu, Peng Pu, Dan Jiang, Dongying Zhang. Real-world challenges for guideline-directed medical therapy intolerance in heart failure: a single-center prospective cohort study. International Journal of Cardiology, 2025, 434:133367. IF=3.2.

3. Shiwei Qin, Meilin Xiang, Lei Gao, Xiaocheng Cheng, Dongying Zhang. Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis. ESC Heart Failure, 2024, 11(1):78–90. IF=3.8.

4. Xiaocheng Cheng, Hanru Zhao, Xuesong Wen, Guoxing Li, Shuliang Guo, Dongying Zhang. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. Life Sciences, 2023, 333:122185. IF=5.2.

5. Xiaocheng Cheng, Hanru Zhao, Xuesong Wen, Guoxing Li, Shuliang Guo, Dongying Zhang. NLRP3-inflammasome inhibition by MCC950 attenuates cardiac and pulmonary artery remodelling in heart failure with preserved ejection fraction. Life Sciences, 2023, 333:122185. IF=6.1.

6. Min Sun, Lei Gao, Hongmei Bai, Weiwei Hu, Xiaofang Zhang, Jin Xiao, Xiangliang Deng, Hongmei Tao, Ping Ge, Yuhong Qin, Dongying Zhang. Association between visceral fat, blood pressure and arterial stiffness in patients with HFpEF: a mediation analysis. Diabetes, Metabolic Syndrome and Obesity, 2023, 16:653–662. IF=3.3.

7. Xiang-Liang Deng, Han-Wen Yi, Jin Xiao, Xiao-Fang Zhang, Jin Zhao, Min Sun, Xue-Song Wen, Zhi-Qiang Liu, Lei Gao, Zi-Yang Li, Ping Ge, Qi Yu, Dongying Zhang. Serum uric acid: a risk factor for right ventricular dysfunction and prognosis in heart failure with preserved ejection fraction. Frontiers in Endocrinology, 2023, 14:1143458. IF=3.9.

8. Jie Liu, Qi Yu, Ziyang Li, Yujiao Zhou, Zhiqiang Liu, Linna You, Li Tao, Qian Dong, Ziyu Zuo, Lei Gao, Dongying Zhang. Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study. Cardiovascular Diabetology, 2023, 22(1):45. IF=9.8.

9. Qin Duan, Dongying Zhang, Qian Dong, Kangla Liao, Yunjin Yang, Liu Ye, Ping Ge, Shu Qin. Impact of brachial-ankle pulse wave velocity on myocardial work by non-invasive left ventricular pressure-strain in patients with preserved ejection fraction. Frontiers in Cardiovascular Medicine, 2022, 9:814326. IF=6.05.

10. Zhiqiang Liu, Weiwei Hu, Hanwen Zhang, Hongmei Tao, Peng Lei, Jie Liu, Yali Yu, Qian Dong, Lei Gao, Dongying Zhang. Epicardial adipose tissue thickness as a predominant feature for evaluating arterial stiffness in HFpEF. Diabetes, Metabolic Syndrome and Obesity, 2022, 15:1217–1226. IF=3.168.

11. Xue-Song Wen, Luo Rui, Liu Jie, Zhiqiang Liu, Hanwen Zhang, Weiwei Hu, Duan Qin, Shu Qin, Xiao Jin, Dongying Zhang. The duration of beta-blocker therapy and outcomes after acute myocardial infarction. Clinical Cardiology, 2022. IF=2.882.

12. Xuesong Wen, Luo Rui, Liu Jie, Duan Qin, Shu Qin, Xiao Jun, Dongying Zhang. Short-term and long-term prognosis with or without beta-blockers after acute myocardial infarction. BMC Cardiovascular Disorders, 2022, 22:193. IF=2.298.

13. Xiaocheng Cheng, Liyou Wang, Xuesong Wen, Lei Gao, Guoxing Li, Guanglei Chang, Shu Qin, Dongying Zhang. TNAP is a novel regulator of cardiac fibrosis after myocardial infarction. EBioMedicine, 2021, 67:103370. IF=8.143.

14. Yuqian Guo, Guoxing Li, Lei Gao, Xiaocheng Cheng, Liyou Wang, Yuhong Qin, Dongying Zhang. Exaggerated renal fibrosis in lncRNA Gas5-deficient mice. Life Sciences, 2021, 264:118656. IF=5.2.

15. Xue-Song Wen, Dan Jiang, Lei Gao, Jian-Zhong Zhou, Jun Xiao, Xiaocheng Cheng, Bin He, Yue Chen, Peng Lei, Xiao-Wei Tan, Shu Qin, Dongying Zhang. Clinical characteristics and predictive value of CD4+ T cell level in COVID-19. Respiratory Research, 2021, 21:57. IF=3.09.

16. Lei Gao, Li-You Wang, Zhi-Qiang Liu, Dan Jiang, Shi-Yong Wu, Yu-Qian Guo, Hong-Mei Tao, Min Sun, Lin-Na You, Shu Qin, Xiao-Cheng Cheng, Jun-Shi Xie, Guang-Lei Chang, Dongying Zhang. TNAP inhibition attenuates cardiac fibrosis after myocardial infarction. Cell Death & Disease, 2020, 11:44. IF=8.469.

17. Xiaocheng Cheng, Guoqiang Cai, Xuesong Wen, Lei Gao, Dan Jiang, Min Sun, Shu Qin, Jianzhong Zhou, Dongying Zhang. Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19. Aging (Albany NY), 2020, 12:23436–23449. IF=5.682.

18. Lei Gao, Dan Jiang, Xue-Song Wen, Xiao-Cheng Cheng, Min Sun, Bin He, Lin-Na You, Peng Lei, Xiao-Wei Tan, Shu Qin, Guo-Qiang Cai, Dongying Zhang. Prognostic value of NT-proBNP in patients with severe COVID-19. Respiratory Research, 2020, 21:83. IF=5.631.

19. Dan Jiang, Ying Wang, Guanglei Chang, Qin Duan, Linna You, Min Sun, Chunxiao Hu, Lei Gao, Shiyong Wu, Hongmei Tao, Kai Lu, Dongying Zhang. DNA hydroxymethylation combined with carotid plaques as a biomarker for coronary atherosclerosis. Aging, 2019, 11:3170–3181. IF=5.682.

20. Xuexiu Luo, Shiyong Wu, Youqing Jiang, Liyou Wang, Guoxing Li, Yuhong Qing, Jian Liu, Dongying Zhang. Geniposide protects against myocardial ischemia/reperfusion injury. International Immunopharmacology, 2020, 85:106609. IF=4.932.

21. Liu Ye, Hong-Mei Bai, Dan Jiang, Bing He, Xue-Song Wen, Ping Ge, Dongying Zhang. Combination of eosinophil percentage and hs-CRP predicts MACE in STEMI. Journal of Clinical Laboratory Analysis, 2020, 34:e23367. IF=2.352.

22. Dan Jiang, Min Sun, Linna You, Kai Lu, Lei Gao, Chunxiao Hu, Shiyong Wu, Guanglei Chang, Hongmei Tao, Dongying Zhang. DNA methylation and coronary atherosclerosis. Life Sciences, 2019, 224:241–248. IF=5.037.

23. Xiaocheng Cheng, Qiongwen Hu, Lei Gao, Jian Liu, Shu Qin, Dongying Zhang. Sex-related differences in catheter ablation of atrial fibrillation. Europace, 2019, 21:1509–1518. IF=5.214.

24. Xiaocheng Cheng, Qiongwen Hu, Hanru Zhao, Shu Qin, Dongying Zhang. Transcatheter versus surgical aortic valve replacement in CKD. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33:2221–2230. IF=2.628.

25. Guanglei Chang, Jian Liu, Shu Qin, Youqin Jiang, Peng Zhang, Hui Yu, Kai Lu, Nan Zhang, Li Cao, Ying Wang, Yong Li, Dongying Zhang. Cardioprotection by exenatide via mitochondrial function. International Journal of Molecular Medicine, 2018, 41:1693–1703. IF=4.101.

26. Peng Zhang, Chunxiao Hu, Yongyong Li, Ying Wang, Lei Gao, Kai Lu, Guanglei Chang, Yong Li, Shu Qin, Dongying Zhang. Vangl2 is essential for myocardial remodeling. Experimental Cell Research, 2018, 365:33–45. IF=3.3.

27. Aihua Zheng, Li Cao, Shu Qin, Yue Chen, Yong Li, Dongying Zhang. Exenatide regulates substrate preference after ischemia/reperfusion injury. Experimental and Therapeutic Medicine, 2017, 26:404–412. IF=2.975.

28. Jun Jia, Guang-Lei Chang, Shu Qin, Jia Chen, Wen-Yan He, Kai Lu, Yong Li, Dongying Zhang. Copeptin versus NT-proBNP in acute decompensated heart failure. Experimental and Therapeutic Medicine, 2017, 13:1554–1560. IF=2.447.

29. Kai Lu, Guanglei Chang, Lin Ye, Peng Zhang, Yong Li, Dongying Zhang. Protective effects of exendin-4 on hypoxia/reoxygenation-induced injury. Molecular Medicine Reports, 2015, 12:3007–3016. IF=3.4.

30. Ying Wang, Aihua Zheng, Yunsheng Yan, Fei Song, Qianran Kong, Shu Qin, Dongying Zhang. Association between adiponectin and early-onset coronary artery disease. Atherosclerosis, 2014, 235:392–397. IF=4.9.

31. Wenyan He, Jun Jia, Jia Chen, Shu Qin, Hongmei Tao, Qianran Kong, Qiu Xue, Dongying Zhang. RDW versus NT-proBNP in acute heart failure. International Heart Journal, 2014, 55:58–64. IF=1.2.

32. Guanglei Chang, Peng Zhang, Lin Ye, Kai Lu, Ying Wang, Qin Duan, Aihua Zheng, Shu Qin, Dongying Zhang. Protective effects of sitagliptin on myocardial ischemia/reperfusion injury. European Journal of Pharmacology, 2013, 718:105–113. IF=4.2.

1. 心外膜脂肪经 Adipsin/Dusp26 参与射血分数保留心力衰竭心脏重塑的机制研究，国家自然科学基金委员会（项目编号 8227022091），52万，2023- 01至 2026-12, 项目负责人张冬颖（在研）。

2. AMKP-P53介导Akp2对心脏纤维化的作用及机制研究，国家自然科学基金委员会(项目编号81970209)，55万，2020-01至 2023-12，项目负责人张冬颖（已结题）。

3. Insl6对心肌纤维化的影响及机制研究，国家自然科学基金委员会(项目编号81570212)，60万，2016-01到2019-12，项目负责人张冬颖（已结题）。

4. 脂联素蛋白异构体和启动子基因多态性对冠状动脉粥样硬化的影响。国家自然科学基金委员会（项目编号81100196），23万，2017.01至2019.12，项目负责人张冬颖（已结题）。

5. 心外膜脂肪经 Cfd/补体途径参与射血分数保留心力衰竭心脏重塑的机制研究，重庆市科教联合项目，项目编号（2024NSCQ-LZX0092），50万，2024- 07-01至 2027-06-30, 项目负责人张冬颖（在研）。

6. 心梗后β受体阻滞剂的精准用药对预后的影响，重庆市卫生健康委员会(项目编号cstc2021jcyj-msxmX0028)，10万，2022-01至2024-12，项目负责人张冬颖。

7. 探索反应心肌纤维化程度及预后的生物性标志物，重庆市人力资源和社会保障局，10万，2019-11至2022-12，项目负责人张冬颖。（已结题）

8. ALP对心肌纤维化的影响及相关机制，重庆市自然科学基金(项目编号2018QNXM024），10万，2018-02至2021-12，项目负责人张冬颖（已结题）。

9. 京尼平苷调控自噬对糖尿病心肌损伤，重庆市卫计委中医药科技项目（项目编ZY201702073）,6万元，2017-04至2020-06, 项目负责人张冬颖（已结题）。

10. 自噬在曲美他嗪保护心肌缺血再关注损伤中的地位，中国心血管健康联盟心脏康复与代谢治疗研究基金，5万，2017.01至2019.12，项目负责人张冬颖（已结题）。

11. TNAP经Sirt1-PGC1α调控心脏能量底物重塑驱动氧化应激的机制研究，国家自然科学基金委员会（项目编号82300372），30万，2024- 01至 2026-12, 项目负责人高磊，项目指导和第一参与人张冬颖（在研）。

12. TNAP通过激活TGF-β/Smad信号通路调控心肌纤维化的机制研究，国家自然科学基金委员会青年科学基金项目(项目编号31800379)，26万元，2019-01-01至2021-12-31, 项目负责人常广磊，项目指导和第一参与人张冬颖（已结题）。

13. 基于不同联合方式在基层医院建立法布里高危人群诊筛体系。中国健康促进基金会罕见病诊疗与管理科研基金项目，10万，2025.01-2025.12，项目负责人张冬颖（在研）。

14. 万人家庭血压达标行动前瞻性登记研究项目（REATION-HBP）重庆分中心，横向课题，经费10万，2021.01-2026.12，项目负责人张冬颖（在研）。

15. EVOLUTION全国研究项目重庆中心，经费10万。

16. 艾司洛尔与胺碘酮治疗近期发作房颤的有效性研究，心血管多学科整合思维研究基金，中华国际医学交流基金会，经费8万，2019.01-2021.12，项目负责人张冬颖（已结题）。

17. PCSK9抑制剂对乳腺癌合并高胆固醇血症患者降脂疗效及肿瘤预后的影响, 中国心血管健康联盟心馨心血管健康基金, 经费10万，2022.01-2023.12，项目负责人高磊，项目第一参与人张冬颖（已结题）。

18. 克隆造血对急性心肌梗死的影响，中国心血管健康联盟心馨心血管健康基金(基金编号2018-CAA-AF-034), 经费10万，2019.01-2020.12，项目负责人常广磊，项目第一参与人张冬颖（已结题）。

19. 左西孟旦对VA-ECMO患者撤机成功率及预后的观察性研究，心血管多学科整合思维研究基金，中华国际医学交流基金会，经费5万，2019.01-2021.12，项目负责人叶林，项目指导和第一参与人张冬颖（已结题）。